Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine

Drug resistance underpins poor outcomes in many malignancies including refractory and relapsed acute myeloid leukemia (R/R AML). Glucuronidation is a common mechanism of drug inactivation impacting many AML therapies, e.g., cytarabine, decitabine, azacytidine and venetoclax. In AML cells, the capaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Assouline, Sarit, Gasiorek, Jadwiga, Bergeron, Julie, Lambert, Caroline, Culjkovic-Kraljacic, Biljana, Cocolakis, Eftihia, Zakaria, Chadi, Szlachtycz, David, Yee, Karen, Borden, Katherine L.B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Acute Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620574/
https://www.ncbi.nlm.nih.gov/pubmed/36951168
http://dx.doi.org/10.3324/haematol.2023.282791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620574/
https://www.ncbi.nlm.nih.gov/pubmed/36951168
http://dx.doi.org/10.3324/haematol.2023.282791

Ejemplares similares